Wakeman SE, Larochelle MR, Ameli O, Chaisson C, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2): e1920622.

Article  PubMed  PubMed Central  Google Scholar 

Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28(4):321–9.

Article  PubMed  Google Scholar 

Institute of Medicine Committee on Federal Regulation of Methadone Treatment. Federal Regulation of Methadone Treatment. In: Rettig RA, Yarmolinsky A, Eds. Federal Regulation of Methadone Treatment. National Academies Press; 1995:120–150.

Harris J, McElrath K. Methadone as social control: institutionalized stigma and the prospect of recovery. Qual Health Res. 2012;22(6):810–24. https://doi.org/10.1177/1049732311432718.

Article  PubMed  Google Scholar 

Drug Addiction Treatment Act, 1101, §3501. 2000. https://www.govinfo.gov/content/pkg/PLAW-106publ310/pdf/PLAW-106publ310.pdf. Accessed 24 Mar 2020.

Pew Charitable Trusts. Overview of opioid treatment program regulations by state: restrictive rules put evidence-based medication treatment out of reach for many. September 2022. See https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2022/state-opioid-treatment-program-regulations-put-evidence-based-care-out-of-reach-for-many and https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2022/09/overview-of-opioid-treatment-program-regulations-by-state

U.S. Substance abuse and mental health services administration. Federal guidelines for opioid treatment programs. Substance Abuse and Mental Health Services Administration; 2015.

Henry-Edwards S, Gowing L, White J, Ali R, Bell J, Brough R, Lintzeris N, Ritter A, Quigley A. Clinical guidelines and procedures for the use of methadone in the maintenance and treatment of opioid dependence. Publications Production Unit, Australian Government Department of Health and Ageing, 2003; Publication approval number: 3263 (JN 7616).

Calcaterra SL, Chadi BPA, et al. Methadone matters: What the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019;34(6):1039–42.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Klimas J, Hamilton M-A, Gorfinkel L, Adam A, Cullen W, Wood E. Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials. Syst Rev. 2021;10:216. https://doi.org/10.1186/s13643-021-01764-9.

Article  PubMed  PubMed Central  Google Scholar 

Moradinazar M, Farnia V, Alikhani M, Karyani AK, Rezaei S, Rezaeian S, Matin BK, Najafi F. Factors related to relapse in patients with substance-related disorders under methadone maintenance therapy: decision tree analysis. Oman Med J. 2020;35(1): e89. https://doi.org/10.5001/omj.2020.07.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dunn KE, Brooner RK, Stoller KB. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the COVID-19 pandemic. J Sub Abuse Treat. 2021;121: 108197. https://doi.org/10.1016/j.jsat.2020.108197.

Article  CAS  Google Scholar 

U.S. Substance Abuse and Mental Health Services Administration (SAMHSA). Opioid Treatment Program Directory. https://dpt2.samhsa.gov/treatment/directory.aspx Accessed 23 April 2024.

U.S. Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS): 2020. Data on Substance Abuse Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2021

Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Subst Abust Treat. 2021;123:1–4.

Google Scholar 

Walley AY, Cheng DM, Pierce CE, Chen C, Filippell T, Samet JH, Alford DP. methadone dose, take home status, and hospital admission among methadone maintenance patients. J Addict Med. 2012;6(3):186–90.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Honoria G. “It’s like ‘liquid handcuffs”: the effects of take-home dosing policies on methadone maintenance treatment (MMT) patients’ lives. Harm Reduct J. 2021;18:88.

Article  PubMed  PubMed Central  Google Scholar 

Russell DM. To a US methadone recipient, visiting Australia was shocking. Filter 2022; December 20. [online]: https://filtermag.org/methadone-clinic-australia-pharmacy/ Accessed 12 Feb 2023.

Russell DM. Naturally Non-compliant: mandatory counseling in methadone clinics. (Unpublished doctoral dissertation). Arizona State University. Tempe, Arizona. 2023.

Marshall K, Maina G, Sherstobitoff J. Plausibility of patient-centered care in high-intensity methadone treatment: reflections of providers and patients. Addict Sci Clin Pract. 2021;16:42.

Article  PubMed  PubMed Central  Google Scholar 

Bowser D, Bohler R, Davis MT, Hodgkin D, Frank RG, Horgan CM. New methadone treatment regulations should be complemented by payment and financing reform. Health Affairs Forefront. 2023. https://doi.org/10.1377/forefront.20230531.974690.

Article  Google Scholar 

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62:593–602.

Article  PubMed  Google Scholar 

Villagómez RE, Meyer TJ, Lin MM, Brown LS. Post-traumatic stress disorder among inner city methadone maintenance patients. J Subst Abuse Treat. 1995;12(4):253–7.

Article  PubMed  Google Scholar 

Madden EF. Intervention stigma: how medication-assisted treatment marginalizes patients and providers. Soc Sci Med. 2019;232:324–31. https://doi.org/10.1016/j.socscimed.2019.05.027.

Article  PubMed  Google Scholar 

National Institutes of Health. 1997. The NIH Consensus Development Program: Effective Medical Treatment of Opiate Addiction [Consensus Development Conference Statement]. https://consensus.nih.gov/1997/1998treatopiateaddiction108html.htm

Joudrey PJ, Chadi N, Roy P, Morford K, Bach P, Kimmel S, Wang EA, Calcaterra SL. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: a cross-sectional study. Drug Alco Depend. 2020;211: 107968.

Article  CAS  Google Scholar 

D’Aunno T, Pollack H. Changes in methadone treatment practices: results from a national panel study, 1988–2000. JAMA. 2002;88(7):850–6.

Article  Google Scholar 

United States Substance Abuse and Mental Health Services Administration (SAMHSA). FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency, April 21, 2020. https://tinyurl.com/sxbcnh3

Health and Human Services, Substance Abuse and Mental Health Services Administration. Code of Federal Regulations 42 Part 8: Medications for the Treatment of Opioid Use Disorder. [https://www.federalregister.gov/documents/2024/02/02/2024-01693/medications-for-the-treatment-of-opioid-use-disorder} Accessed 23 April 2024.

Treitler PC, Bowdewn CF, Lloyd J, Enich M, Nyaku AN, Crystal S. Perspectives of opioid use disorder treatment providers during COVID-19: adapting to flexibilities and sustaining reforms. J Sub Ab Treat. 2022;132:108514.

Article  CAS  Google Scholar 

Krawczyk N. Lessons learned from COVID-19 and regulatory change in the wake of necessity. Report to the National Academies of Science, 2022. https://www.nationalacademies.org/documents/embed/link/LF2255DA3DD1C41C0A42D3BEF0989ACAECE3053A6A9B/file/D3E063A30D9D988E5EB95D66B10AABA47900519FC319

Meyerson BE, Bentele KG, Brady BR, Stavros N, Russell DM, Mahoney A, Garnett I, Jackson S, Garcia RC, Coles H, Granillo B, Carter GA. Insufficient impact: Limited implementation of federal regulatory changes to methadone and buprenorphine access in Arizona during COVID. Am J Prev Med Focus. 2023. https://doi.org/10.1016/j.focus.2023.100177.

Article  Google Scholar 

Brothers S, Viera A, Heimer R. Changes in methadone program practices and fatal methadone overdose rates in connecticut during COVID-19. J Sub Abuse Treat. 2021;131: 108449.

Article  CAS  Google Scholar 

Meyerson BE, Bentele KG, Russell DM, Brady BR, Downer M, Garcia RC, Garnett I, Lutz R, Mahoney A, Samorano S, Arredondo C, Andres HJ, Coles H, Granillo B. Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID. PLoS ONE. 2022;17(10): e0274094.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jones CM, Shoff C, Hodges K, et al. Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among medicare beneficiaries before and during the COVID-19 pandemic. JAMA Psychiat. 2022;79(10):981–92.

Article  Google Scholar 

Mandavia AD, Campbell A, Henry BF, et al. Support for COVID-19-related substance use services policy changes: a New York state-wide survey. J Behav Health Serv Res. 2022;49:262–81. https://doi.org/10.1007/s11414-021-09784-y.

Article  PubMed  PubMed Central  Google Scholar 

Fuller BE, Rieckmann T, Nunes EV, Miller M, Arfken C, Edmundson E, McCarty D. Organizational readiness for change and opinions toward treatment innovations. J Sub Abuse Treat. 2007;33:183–92. https://doi.org/10.1016/j.jsat.2006.12.026.

Article  Google Scholar 

Frimpong JA, Guerrero EG, Kong Y, Khachikian T, Wang S, D’Aunno T, Howard DL. Predicting and responding to change: perceived environmental uncertainty among substance use disorder treatment programs. J Sub Use Addic Treat. 2023;145: 208947. https://doi.org/10.1016/j.josat.2022.208947.

Article  CAS  Google Scholar 

Pasman E, Lee G, Kollin R, Rodriguez B, Agius E, Madden EF, Resko SM. Attitudes toward medication for opioid use disorder among substance use treatment providers. Subs Misuse. 2022. https://doi.org/10.1080/10826084.2022.211.5853.

Article  Google Scholar 

Aletraris L, Edmond MB, Paino M, Fields D, Roman PM. Counselor training and attitudes toward pharmacotherapies for opioid use disorder. Substance Abuse. 2016;37(1):47–53. https://doi.org/10.1080/08897077.2015.1062457.

Article  PubMed  Google Scholar 

Broman MJ, Pasman E, Brown S, Lister JJ, Agius E, Resko SM. Social support is associated with reduced stigma and shame in a sample of rural and small urban adults in methadone treatment. Addict Res Theor. 2022. https://doi.org/10.1080/16066359.2022.2101640.